Pulmonary Sarcoidosis with Cough: What to Do When Steroid-Sparing Agents Did Not Achieve Clinical Effectiveness
This protocol targets pulmonary sarcoidosis presenting with mild respiratory symptoms — specifically persistent cough without dyspnea — in patients for whom previous steroid-sparing therapy did not achieve adequate clinical effectiveness within the expected period.
Clinical Scenario
Pulmonary sarcoidosis with mild respiratory symptoms including cough, in the absence of dyspnea. Initial therapy for patients with these mild symptoms typically involves inhaled corticosteroids.
Previous Treatment — Goals Not Achieved
Prior steroid-sparing therapy — including agents such as methotrexate, azathioprine, mycophenolate, or leflunomide — did not achieve clinical effectiveness within 6 months. This protocol defines the escalation step taken after that failure.
Next-Line Approach (Partial)
When prior therapy has not produced clinical effectiveness, the next step involves consideration of an anti-TNF agent. The complete agent selection, criteria, and administration details are contained in the full protocol.
Treatment Goal
Improvement in pulmonary inflammatory changes, with benefits expected within 3–6 months of initiating the appropriate agent.
References
- For patients with mild symptoms, such as a cough, treatment should begin with inhaled corticosteroids.
- If no alternative cause of dyspnea is identified, an anti-TNF agent should be considered.
- Infliximab has been widely studied, although adalimumab at higher doses may be effective.
- These agents have proved effective for treating inflammatory changes in the lung but will not reverse fibrosis.
- Benefits are usually seen within 3–6 months of starting one of these agents.
View source ↗